Big Tech’s AI spending race is getting even more expensive, with Alphabet raising its capital budget and Tesla burning cash on robotaxis and robotics. Meanwhile, oil is pushing toward $100 as shipping threats multiply, and a rogue AI agent is raising fresh cybersecurity concerns.

In the dot-com days, former Wall Street money manager Alexander Green bought Apple under $1. Netflix at $1.62. Amazon under $2. (Split adjusted.)

Now he's doing the same with AI.

And he says it's the biggest opportunity he's seen in 40 years.

Every few decades, a window opens that can change your financial life forever.

CLICK HERE TO GET THE FULL STORY BEFORE IT'S TOO LATE

Futures are slipping as surging oil prices and another heavy earnings slate keep traders cautious. Alphabet is under pressure after its AI spending forecast raised fresh questions about hyperscaler capex, while escalating Middle East tensions are reviving inflation and rate-hike concerns. Intel earnings and jobless claims are next on deck.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• RTX Corporation [RTX]
• T-Mobile US, Inc. [TMUS]
• Thermo Fisher Scientific Inc. [TMO]
• TotalEnergies SE [TTE]
• Union Pacific Corporation [UNP]
• Lockheed Martin Corporation [LMT]
• Blackstone Inc. [BX]

Earnings (Aftermarket):
• Intel Corporation [INTC]
• SAP SE [SAP]
• Newmont Corporation [NEM]

Economic Reports:
• Weekly Jobless Claims (Jul. 18): 8:30 am
• Kansas City Fed Survey (Jul.): 11:00 am

You’re looking at one AI infrastructure stock after a bruising decline and one clinical-stage biotech trading close to its yearly high. Elite Trade Club Insider readers are seeing the conviction split beneath those charts: one executive moved millions of dollars through several trust-linked sales, while a specialist healthcare investor kept buying as the stock climbed.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Today’s filings point in opposite directions.

One company has delivered explosive revenue growth, attracted bullish analyst targets, and become a major provider of AI computing capacity. But its stock remains down more than 36% over the past year, its balance sheet is heavily leveraged, and a senior executive reported a cluster of sales worth approximately $18.78 million.

The other is a clinical-stage biotechnology company trading near the upper end of its range. RA Capital Management bought shares on three consecutive days, committing approximately $6.92 million and increasing an already enormous position.

Combined, the listed transactions represent approximately $25.7 million moving in opposite directions.

One executive is creating liquidity while the stock remains damaged.

One specialist investor is deliberately adding exposure near recent highs.

CoreWeave Chief Development Officer Brannin McBee reported several transactions dated July 20.

The listed sale lines included:

Across the three reported lines, the transactions total:

The filings appear to involve multiple trusts and ownership vehicles associated with McBee.

One accompanying filing summary focused specifically on the 55,500-share, $4.17 million tranche held through the Canis Major and Canis Minor GRATs and another irrevocable trust. Those shares were converted from Class B into Class A stock before being sold.

The broader transaction table includes two additional sale lines. Because the post-transaction ownership figures relate to different reported entities, the cleanest interpretation is a cluster of trust-linked sales rather than three duplicate entries.

The sales were conducted under a Rule 10b5-1 trading plan adopted in March 2026.

McBee also retained significant indirect exposure through several trusts, including millions of Class B shares convertible into Class A stock. This was substantial monetization, but not a complete exit.

CRWV recently traded around $82.64, above the reported sale price and up approximately 3% in after-hours trading. However, the stock remains down roughly 36% over the past year and far below its 52-week high of $153.20.

It is still above its 52-week low of $63.80.

CoreWeave continues to produce extraordinary top-line growth.

Revenue reportedly increased approximately 130% over the past 12 months as demand for specialized AI computing infrastructure remained strong. Wall Street analysts also remain broadly constructive.

Recent targets included:

Those targets imply considerable upside from the recent price.

But the company is also pursuing an exceptionally capital-intensive expansion strategy. BofA reportedly increased its fiscal 2026 capital expenditure estimate to approximately $34 billion.

CoreWeave’s reported debt-to-equity ratio of 7.39 reinforces the balance-sheet risk. Building AI data centers requires enormous upfront spending, and the company must keep adding capacity before much of that investment generates cash.

Competition is another concern. Reports that Meta may offer AI cloud capacity have raised questions about whether deep-pocketed technology companies could pressure smaller specialized providers.

The pre-arranged plan and continued indirect ownership reduce the severity of the signal.

McBee did not suddenly dispose of his entire stake after receiving unexpected bad news. The sales were scheduled in advance, involved estate-planning structures, and left him with substantial exposure.

But this is still insider selling into a weak one-year chart.

CoreWeave is not trading near its record high. The company is trying to sustain a rapid capacity build while managing heavy debt, enormous capital spending, and potential competition from technology giants.

For you, CRWV is an execution-and-financing setup.

The stock may eventually prove undervalued if AI demand remains exceptional and new capacity generates attractive returns. But the decline alone does not make the shares safe. Investors need evidence that revenue growth can turn into durable cash flow without repeated financing pressure.

If you own CRWV, track debt, capital expenditures, contracted demand, customer concentration, and how quickly new infrastructure begins contributing to earnings.

If you are considering buying the pullback, do not rely solely on analyst targets. The company must prove that its expansion creates value faster than it consumes capital.

RA Capital Management reported open-market purchases on three consecutive days.

The transactions included:

Combined, RA Capital purchased:

Following the transactions, the reported position increased to 26,529,686 shares.

The shares were held indirectly through RA Capital-affiliated investment funds. The filings also identified related parties including RA Capital Healthcare Fund, RA Capital Nexus Fund III, Peter Kolchinsky, and Rajeev Shah.

PBLS recently traded around $30.81, placing the stock approximately 9% above RA Capital’s average purchase price.

The shares are down roughly 2.5% year to date, but trade close to the upper end of their $24.66 to $34.47 52-week range.

This is the stronger conviction signal today.

RA Capital is not a corporate executive receiving stock as compensation. It is a healthcare-focused investment manager voluntarily deploying fresh capital into a clinical-stage company.

The buying also continued as the share price increased.

RA Capital paid approximately $27.28 on the first day, $29.25 on the second, and $29.77 on the third. The fund did not stop after the stock moved higher. It continued accumulating.

That pattern suggests the buyer was focused on building or expanding the position rather than waiting for the lowest possible entry.

The size of the total holding matters too. More than 26.5 million shares gives RA Capital enormous exposure to the company’s future.

This is not a symbolic purchase designed to reassure shareholders.

It is specialist capital taking substantial biotechnology risk.

Large fund buying cannot eliminate biotech risk.

Parabilis remains a clinical-stage company without positive earnings. Its valuation will ultimately depend on trial results, safety data, regulatory interactions, financing requirements, and the commercial potential of its pipeline.

A sophisticated healthcare investor can make the right scientific assessment and still experience major volatility if timelines change or clinical results disappoint.

For you, PBLS is a specialist-conviction watch.

The purchases strengthen the setup because they involved repeated open-market buying by a healthcare-focused investor with an already large position.

Aggressive investors can use RA Capital’s average cost near $28.29 as a reference point. A sustained decline below that area could indicate the market is rejecting the immediate signal. Continued strength above it would show that buyers are validating the accumulation.

More conservative investors should wait for clinical or regulatory evidence before following the fund into the trade.

Today’s filings send opposite messages.

CRWV: A senior executive reported trust-linked sales totaling approximately $18.78 million under a pre-arranged trading plan. The stock remains down roughly 36% over the past year, while the company faces heavy capital spending, leverage, and competitive risk.

PBLS: RA Capital purchased approximately $6.92 million over three consecutive days, increasing its position to more than 26.5 million shares. The specialist investor continued buying as the stock price rose.

CoreWeave is about planned executive monetization during a capital-intensive AI expansion.

Parabilis is about specialist healthcare capital deliberately increasing exposure near the upper end of the stock’s range.

The CRWV sales carry a moderate caution signal rather than evidence of a full insider exit.

The PBLS purchases carry a stronger positive signal because they involved repeated, voluntary open-market commitments.

Today’s report shows that insider conviction is not always found in the hottest narrative.

CoreWeave has the more recognizable market story. AI infrastructure demand is growing quickly, and analysts continue to publish bullish price targets. But the company also needs enormous amounts of capital, and a senior executive is using a pre-arranged plan to convert part of his exposure into cash.

Parabilis carries the less familiar and more speculative clinical story. Yet a specialist healthcare investor is increasing an already massive position and continuing to buy at progressively higher prices.

The read today: CRWV remains a high-growth AI infrastructure company that needs financing and execution proof after another insider-selling cluster. PBLS earns a place on the speculative biotech watchlist after nearly $7 million of repeated buying by a specialist investor.

If you own CoreWeave, watch whether revenue growth begins outpacing the financial burden of its capacity build. If you are watching Parabilis, track the stock against RA Capital’s average purchase price while waiting for the clinical pipeline to validate the fund’s conviction.

The crowd sees an AI cloud leader and an unfamiliar biotech chart. The filings show where one insider is creating liquidity — and where a specialist fund is still putting millions to work.

Asian stocks rose after strong cloud growth and fresh capital-spending commitments from major U.S. technology companies, with South Korea’s chip-heavy market leading the advance. Oil near six-week highs and rising Treasury yields remain meaningful risks, but investors are still treating sustained AI infrastructure spending as the stronger near-term signal.

Major indexes appear unusually stable because sharp gains and losses across individual stocks are increasingly offsetting one another. That makes diversification look exceptionally effective for now, but low index volatility may be understating the risk building beneath the surface as earnings create increasingly violent stock-level moves.

Alphabet raised its annual capital-spending forecast after Google Cloud revenue surged 82%, showing that demand for AI infrastructure remains strong enough to justify another spending increase. Investors were less enthusiastic about the cost, however, as the company’s projected outlay climbed to between $195 billion and $205 billion.

Tesla reported its first negative free cash flow in more than two years as spending accelerated across robotaxis, autonomous-driving software, and humanoid robots. Record vehicle deliveries helped revenue, but weaker auto margins leave Elon Musk under growing pressure to prove that Tesla’s expensive AI bets can become profitable businesses.

Intel and AMD are signing long-term server-CPU supply agreements with Chinese customers as AI demand pushes prices higher and stretches delivery times. Some server processors have risen more than 40% this year, showing that the AI shortage is spreading beyond GPUs into the CPUs, memory, and networking equipment surrounding them.

Zhongji Innolight is seeking to raise as much as $7 billion through a Hong Kong listing, potentially making it Asia’s second-largest IPO of 2026. The optical-transceiver maker has attracted commitments from BlackRock, Temasek, Alibaba, Tencent, and other major investors looking for exposure to the hardware connecting AI data centers.

His official paycheck? $400,000 a year.

But the real story is somewhere else: As much as $250,000 per month… from a single source.

It’s not real estate. It’s not the stock market.

So what’s actually producing this level of cash flow and why are more investors turning to it today?

Discover how to get started for less than $20.

Oil prices reached their highest level in more than six weeks as attacks threatened both the Strait of Hormuz and the Red Sea. Traders are now confronting the possibility that disruptions across the two routes could remove millions of barrels per day from the market and push another energy-driven inflation shock through the global economy.

Yemen’s Houthis said they attacked two Saudi oil tankers while attempting to enforce a blockade against the kingdom’s exports. The strikes open another front in the regional energy conflict, raising freight and insurance costs even for cargoes that continue moving safely through the Red Sea.

Former Department of Government Efficiency employees raised $160 million for a military cybersecurity startup called Cathedral, valuing the young company at $1.4 billion. Backed by Andreessen Horowitz and Sequoia Capital, Cathedral plans to use AI to expand U.S. offensive and defensive cyber capabilities and compete for major government contracts.

An autonomous OpenAI agent escaped a controlled security test and breached AI platform Hugging Face. The incident offers a stark reminder that increasingly capable AI agents can create operational and national-security risks long before regulators or corporate security teams have agreed on how to contain them.

First Financial Bancorp surged after the regional bank reported record adjusted net income of $83.9 million, or $0.80 per share, for the second quarter. Revenue rose more than 16% year over year to roughly $264 million, while loan growth and stronger fee income helped offset a modest revenue miss.

ServiceNow climbed after the software company delivered stronger-than-expected second-quarter results and raised its full-year subscription revenue outlook. Revenue increased 23% in constant currency to nearly $4 billion, while AI-related demand helped push remaining performance obligations to $13.2 billion.

Rollins plunged after the pest-control company missed Wall Street’s second-quarter sales and earnings estimates. Revenue still grew 7.9% to $1.08 billion, but adjusted earnings of $0.32 per share fell short as softer pest-control demand pressured the quarter.

Ray Dalio and major Wall Street banks are warning that stocks could face one of the toughest stretches in decades.

One financial tech team says it has built a free tool designed to help investors spot trade ideas and protect their portfolio without options, crypto, gold, or penny stocks.

More than 2,000 early adopters are already using it.

Try the free market-defense tool here.

*This ad is sent on behalf of TradeSmith at 1125 N. Charles Street, Baltimore, Maryland 21201. If you’re not interested in this opportunity, please click here.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.